Protocol Ledger

NCT07625215 · Phase II · RECRUITING

A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

Interventional Phase II clinical trial protocol NCT07625215 sponsored by Bayer in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-01 Enrollment: 360 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07625215
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)360 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07625215
Protocol FieldVerified Registry Value
NCT IdentifierNCT07625215
Consolidated Lead SponsorBayer
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment360 participants (ESTIMATED)
Registered Start Date2026-09-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI